

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 03 October 2000 (03.10.00)	
International application No. PCT/GB00/00270	Applicant's or agent's file reference KVC/21352WO
International filing date (day/month/year) 31 January 2000 (31.01.00)	Priority date (day/month/year) 29 January 1999 (29.01.99)
Applicant HARPER, E., Jean	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

24 August 2000 (24.08.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Olivia TEFY Telephone No.: (41-22) 338.83.38
---	---

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>KVC/21352W0</b>	<div style="display: flex; justify-content: space-between;"> <div style="text-align: center;"> <b>FOR FURTHER ACTION</b> </div> <div style="font-size: small;">             see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.           </div> </div>	
International application No. <b>PCT/GB 00/ 00270</b>	International filing date (day/month/year) <div style="text-align: center;"><b>31/01/2000</b></div>	(Earliest) Priority Date (day/month/year) <div style="text-align: center;"><b>29/01/1999</b></div>
Applicant  <b>MARS UK LIMITED et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

## INTERNATIONAL SEARCH REPORT

International Application No

P B 00/00270

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/355 A61K31/375 A23K1/16 A23K1/18 A61P9/00  
 A61P13/12 A61P19/02 A61P25/00 A61P27/12 A61P29/00  
 A61P37/00 A61P39/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A23K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 848 955 A (SHOWA DENKO KK) 24 June 1998 (1998-06-24)  page 4, line 54 - line 56 page 5, line 35 - page 7, line 50 example 3 claims 1-9	1,2,5-7, 12-14, 18,20, 21, 23-26,29
Y	---	3,4,30
Y	US 5 141 755 A (WEISMAN ERIC H) 25 August 1992 (1992-08-25) claims 1,4-6,8  ---	3,4,30
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

11 May 2000

Date of mailing of the international search report

24/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Dekeirel, M

## INTERNATIONAL SEARCH REPORT

International Application No

P 00/00270

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI  Section Ch, Week 199723  Derwent Publications Ltd., London, GB;  Class B05, AN 1997-259340  XP002137042  &amp; ZA 9 605 149 A (DAVIS H J),  26 March 1997 (1997-03-26)  abstract</p> <p>---</p>	1,2,5-7, 12-14, 16, 18-24, 26,28
X	<p>K. PRASAD ET AL.: "Oxidative stress as a  mechanism of cardiac failure in chronic  volume overload in canine model"  JOURNAL OF MOLECULAR AND CELLULAR  CARDIOLOGY,  vol. 28, no. 2, 1996, pages 375-385,  XP000909089  ACADEMIC PRESS, LONDON, GB  ISSN: 0022-2828  page 375, abstract</p> <p>---</p>	1,7, 13-15, 18,20, 21,23
P,X	<p>WO 00 01399 A (COASTSIDE BIO RESOURCES  ;COLLIN PETER DONALD (US))  13 January 2000 (2000-01-13)</p> <p>page 1, line 12 - line 15  page 3, line 18 - line 27  examples 1-3</p> <p>---</p>	1,7, 13-15, 18,20, 21,23,24
Y	<p>DATABASE WPI  Section Ch, Week 199521  Derwent Publications Ltd., London, GB;  Class B07, AN 1995-157784  XP002137041  -&amp; JP 07 079712 A (SANEIGEN FFI KK),  28 March 1995 (1995-03-28)  abstract</p> <p>---</p>	1,5-7, 12,13, 23,24
Y	<p>GB 2 185 673 A (MITSUBISHI GAS CHEMICAL  CO) 29 July 1987 (1987-07-29)</p> <p>page 2, line 40 - line 49</p> <p>---</p>	1,5-7, 12,13, 23,24
X	<p>US 3 384 545 A (AIELLO RONALD EUGENE ET  AL) 21 May 1968 (1968-05-21)  column 1, line 67 -column 2, line 22  column 4, line 8 - line 14  examples 1,2,4</p> <p>---</p>	1
X	<p>EP 0 015 721 A (FOX EDWARD SOLOMON)  17 September 1980 (1980-09-17)  example</p> <p>---</p> <p>-/--</p>	25-27,29

## INTERNATIONAL SEARCH REPORT

International Application No

P 8 00/00270

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 834 262 A (NICHIMO KK) 8 April 1998 (1998-04-08) page 5, line 56 -page 6, line 27 page 12, line 51 -page 13, line 17 claims 1-3 ---	7, 13-15, 18, 24
X	WO 97 35491 A (ASTACAROTENE AB ;SVENSKA FODER AB (SE); LIGNELL AAKE (SE); INBORR) 2 October 1997 (1997-10-02) page 1, line 15 - line 21 page 2, line 11 - line 26 claims 1-11 -----	7, 12-16, 18, 19, 24

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 00/00270

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0848955	A	24-06-1998	JP 10175866 A	30-06-1998
			US 5937790 A	17-08-1999
US 5141755	A	25-08-1992	NONE	
ZA 9605149	A		NONE	
WO 0001399	A	13-01-2000	NONE	
JP 7079712	A	28-03-1995	NONE	
GB 2185673	A	29-07-1987	JP 1684153 C	31-07-1992
			JP 3038823 B	11-06-1991
			JP 62158457 A	14-07-1987
			JP 62195254 A	28-08-1987
US 3384545	A	21-05-1968	NONE	
EP 0015721	A	17-09-1980	GB 2042337 A	24-09-1980
EP 0834262	A	08-04-1998	US 6045819 A	04-04-2000
			WO 9737549 A	16-10-1997
WO 9735491	A	02-10-1997	SE 506191 C	17-11-1997
			AU 716605 B	02-03-2000
			AU 2313397 A	17-10-1997
			CA 2249456 A	02-10-1997
			CZ 9803029 A	17-02-1999
			EP 0912106 A	06-05-1999
			NZ 331861 A	28-10-1999
			PL 328996 A	01-03-1999
			SE 9601197 A	28-09-1997

14  
REC'D 17 MAY 2001

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference KVC/21352WO	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/00270	International filing date (day/month/year) 31/01/2000	Priority date (day/month/year) 29/01/1999
International Patent Classification (IPC) or national classification and IPC A61K31/355		
Applicant MARS UK LIMITED et al.		



1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 8 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 24/08/2000	Date of completion of this report 14.05.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Skjöldebrand, C Telephone No. +49 89 2399 8467 

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/00270

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-51 as originally filed

**Claims, No.:**

1-33 as originally filed

**Drawings, sheets:**

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/00270

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 1-6, 18, 19, 23 and 29.

because:

☒ the said international application, or the said claims Nos. 1-6, 18, 19, 23 and 29 with respect to I.A. relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)

Yes: Claims 17, 30-33

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/00270

	No:	Claims	1-16, 18-29
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-33
Industrial applicability (IA)	Yes:	Claims	7-17, 20-22, 24-28, 30-33
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claims 1-6, 18, 19, 23 and 29 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following documents:

D1: EP-A-0 848 955 (SHOWA DENKO KK) 24 June 1998 (1998-06-24)

D2: US-A-5 141 755 (WEISMAN ERIC H) 25 August 1992 (1992-08-25)

D3: DATABASE WPI Section Ch, Week 199723 Derwent Publications Ltd., London, GB; Class B05, AN 1997-259340 XP002137042 & ZA 9 605 149 A (DAVIS H J), 26 March 1997 (1997-03-26)

D4: K. PRASAD ET AL.: 'Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model' JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 28, no. 2, 1996, pages 375-385, XP000909089 ACADEMIC PRESS, LONDON, GB ISSN: 0022-2828

D5: WO 00 01399 A (COASTSIDE BIO RESOURCES ;COLLIN PETER DONALD (US)) 13 January 2000 (2000-01-13)

D6: DATABASE WPI Section Ch, Week 199521 Derwent Publications Ltd., London, GB; Class B07, AN 1995-157784 XP002137041 -& JP 07 079712 A (SANEIGEN FFI KK), 28 March 1995 (1995-03-28)

- D7: GB-A-2 185 673 (MITSUBISHI GAS CHEMICAL CO) 29 July 1987 (1987-07-29)
- D8: US-A-3 384 545 (AIELLO RONALD EUGENE ET AL) 21 May 1968 (1968-05-21)
- D9: EP-A-0 015 721 (FOX EDWARD SOLOMON) 17 September 1980 (1980-09-17)
- D10: EP-A-0 834 262 (NICHIMO KK) 8 April 1998 (1998-04-08)
- D11: WO 97 35491 A (ASTACAROTENE AB ;SVENSKA FODER AB (SE);  
LIGNELL AAKE (SE); INBORR) 2 October 1997 (1997-10-02)

**Novelty - Article 33(2) PCT**

Please refer to the pages, lines etc. indicated in the International Preliminary Search Report.

Document D1 discloses an anti-stress agent for animals, for example dogs and cats, where substances such as vitamin E,  $\beta$ -carotene, lutein and ascorbic acid is included. Document D2 discloses pet food compositions containing vitamin E and C as well as taurine.

The abstract D3 relates to compositions useful in a method for treating virus-infections and boosting the immune-system of animals. The composition comprises  $\alpha$ -tocopherol, vitamin C and  $\beta$ -carotene.

D4 relates to oxidative stress as a mechanism of heart failure in chronic volume overload. Experiments are disclosed where vitamin E were administered to dogs.

D5 discloses dosage forms palatable for dogs, said dosage forms comprising vitamin E and having an antiinflammatory and antiarthritic effect.

Preparations for use as additives in for example pet food, comprising  $\beta$ -carotene and natural vitamin E are described in D6.

D7 teaches that fodder made from oil palm leaf (OPL) contains  $\beta$ -carotene and vitamin E and that it promotes health in domestic animals.

D8 relates to injectable aqueous emulsions of fat soluble vitamins, e.g. vitamin E, suited for parenteral administration to animals.

Document D9 discloses a pharmaceutical composition comprising ascorbic acid, useful for treating canine arthritis.

D10 describes a health-promoting food product/additive, suitable also for pets, and a process for its production. The product comprises antiinflammatory and antioxidation constituents as well as cardiac function improving components.

D11 discloses a carotenoid-containing agent that strengthens the immune defence of

domestic breeding mammals, including dogs.

The disclosure of documents D1-D11 appears to interfere with novelty of method claims 1-6, 18, 19, 24 and 29, product claims 7, 12-16 and 25, use claims 20-23 and 26-28. Novelty of product claims 8-11 appear to be implicitly destroyed (see also comment on clarity under Item VIII).

To summarize: the subject-matter of claims 1-16 and 18-29 is not novel.

**Inventive Step - Article 33(3) PCT**

Antioxidants such as vitamin C and E,  $\beta$ -carotene, lutein and taurine have all been used in pet-food (see novelty above). A particular mixture thereof does not establish an inventive step unless a surprising effect is demonstrated over the single ingredients or known mixtures. Adding another well-known antioxidants, lycopene, does not change this fact. As the beneficial effect of vitamin E and C and  $\beta$ -carotene on the immune system is known (D3), administering such compounds to pets with an immune system compromised due to vaccination appears obvious.

Product claims 17 and 30-33 do therefore appear not to involve an inventive step.

**Industrial Applicability - Article 33(4) PCT**

For the assessment of the present claims 1-23, 26-33 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Re Item VII**

**Certain defects in the international application**

Claims 5, 6, 9-11 appear to have incorrect dependencies.

Method claim 24 relates to claim 21 regarding the foodstuff, but claim 21 is a use claim.

**Re Item VIII**

**Certain observations on the international application**

Method claim 1 defines the subject-matter in terms of the objective to be achieved "...an amount of vitamin E sufficient to increase the plasma vitamin E level". The case is similar for claim 7, because it does not specify the ingredients of the foodstuff. Claims 1, 7 and thereupon dependant claims are therefore not clear (Article 6 PCT).

Claims 15, 27 does not appear to be supported by the description, because there are no data provided demonstrating the substances effect against cancer, ageing, heart disease, atherosclerosis, arthritis, cataracts, inflammatory bowel disease, renal disease, renal failure and neurodegenerative disease (Article 6 PCT).

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> A61K 31/355, 31/375, A23K 1/16, 1/18, A61P 9/00, 13/12, 19/02, 25/00, 27/12, 29/00, 37/00, 39/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 00/44375 <b>(43) International Publication Date:</b> 3 August 2000 (03.08.00)
<b>(21) International Application Number:</b> PCT/GB00/00270 <b>(22) International Filing Date:</b> 31 January 2000 (31.01.00) <b>(30) Priority Data:</b> 9902051.3 29 January 1999 (29.01.99) GB 9928549.6 2 December 1999 (02.12.99) GB <b>(71) Applicant (for all designated States except US):</b> MARS UK LIMITED [GB/GB]; 3D Dundee Road, Slough, Berkshire SL1 4LG (GB). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> HARPER, E., Jean [GB/GB]; Waltham Centre for Pet Nutrition, Waltham-on-the-Wolds, Leicestershire LE14 4RT (GB). <b>(74) Agents:</b> CORNISH, Kristina, Victoria, Joy et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  GBX
<b>(54) Title:</b> ANTIOXIDANT COMPOSITIONS AND METHODS FOR COMPANION ANIMALS  <b>(57) Abstract</b>  The present invention provides, amongst others, a means to overcome the problem of oxidative stress in the domestic cat and dog. There is provided a method for increasing the plasma vitamin E level in a cat or dog, the method comprising the step of administering to said cat or dog, an amount of Vitamin E sufficient to increase the plasma vitamin E level. There is also provided use of vitamin C in the manufacture of a dog or cat foodstuff for the prevention or treatment of a disorder which has a component of oxidative stress. The present invention utilizes antioxidant cocktail to overcome the problem of oxidative stress in a cat or dog. Such cocktail can be used to prevent or treat a disorder which has a component of oxidate stress or to maintain, optimise or boost immunological response.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



### Antioxidant Compositions and Methods for Companion Animals

Free radicals are inherent in the aerobic metabolism of living organisms and are generated by both physiological and pathological processes. They are sometimes  
5 generated intentionally to serve biological functions, such as microbicides in phagocyte cells, or may be accidents of chemistry following which they exhibit destructive behaviours. Whatever their mechanism of generation, if free radical production and removal is not controlled, then their effects on an organism can be  
10 damaging. To combat excessive and inappropriate damage, an elaborate system of antioxidant defences has evolved.

When there is an unbalance between the oxidants and the antioxidants in favour of the oxidants, a condition of oxidative stress exists that can lead to tissue damage.

15 The present invention provides, amongst others, a means to overcome the problem of oxidative stress in the domestic cat and dog.

Accordingly, a first aspect of the invention provides a method for increasing the plasma vitamin E level in a domesticated cat or dog, the method comprising the step of  
20 administering to said cat or dog, an amount of vitamin E sufficient to increase the plasma vitamin E level. The increase may be to the maximum/saturation point measurable in the plasma of the animal. The increase may be in the range of 2 to 3 times the animal's own base line for plasma vitamin E levels (around the maximum physiological increase). The increase may be measured as an increase in the plasma  
25 vitamin E level of up to 25%, preferably 25% or above (preferably up to 50%, or 25 to 50%, or even 50 to 90%) of an individual animal when compared to the plasma vitamin E level when the animal is fed a control diet. The control diet, for example, is such that the total vitamin E consumption for the cat or dog is 10IU/400kcal.

Vitamin E is a collective term for several biologically similar compounds, including those called tocopherols and tocotrienols, which share the same biological activity. The most biologically active biological form of vitamin E (also the most active antioxidant) in animal tissue is alpha-tocopherol. Vitamin E cannot be synthesised *in vivo*. Vitamin E protects against the loss of cell membrane integrity, which adversely alters cellular and organelle function.

Units of vitamin E can be expressed as International Units (IU), where 1 IU of alpha-tocopherol equals 1mg of alpha-tocopherol. Other vitamin E compounds have their IU determined by their biopotency in comparison to alpha-tocopherol as described in McDowell, L.R (1989) Vitamin E: In vitamins in Animal Nutrition, Chapter 4, page 96, Academic Press, UK.

To date, levels of vitamin E above and beyond the minimum levels sufficient to prevent vitamin E deficiency symptoms present in the domestic dog or cat have not been of interest. This invention identifies that the levels of vitamin E in the dog or cat reflect the levels present in their diet and that these levels provide a typical baseline level (see examples) which is not exceeded when the animal is fed on prepared petfood. The present invention shows that the levels of vitamin E in the dog and cat can be increased by incorporating higher levels of vitamin E in the animal's diet (and that this can be achieved by the provision of specialised prepared petfood and/or a cat or dog supplement).

Aspects of the invention provide a means for reducing oxidative stress in the domestic cat and dog. Such a reduction in oxidative stress, in particular strengthens the immune response and provides a healthier animal. Markers of oxidative damage in a dog or cat include, amongst others: plasma carbonyls (end products of protein oxidation), plasma lipid hydroperoxides (markers of lipid oxidation), and anti-LDL antibodies which are produced as a response to LDL oxidation. A decline in any of these is indicative of reduced oxidative damage.

The vitamin E according to the first aspect of the invention may be in any form. It may be a tocopherol or a tocotrienol. It may be alpha-tocopherol, (d- $\alpha$  or dl- $\alpha$ ) beta-tocopherol (d- $\beta$  or dl- $\beta$ ), gamma-tocopherol (d- $\gamma$  or dl- $\gamma$ ), delta-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol or delta-tocotrienol. Preferably it is  
5 alpha-tocopherol.

The source of the vitamin E is not limiting. Preferred vitamin E sources include vitamin E acetate, (e.g tocopherol acetate), vitamin E acetate adsorbate or vitamin E acetate spray dried. Preferred sources are synthetic although natural sources may be  
10 used.

The form of administration of the vitamin E is not limiting. It may be in the form of a diet, foodstuff or a supplement. Hereinafter in this text, the term "foodstuff" covers all of foodstuff, diet and supplement. Any of these forms may be solid, semi-solid or  
15 liquid.

The supplement is particularly useful to supplement a diet or foodstuff which does not contain sufficiently high levels of one or more of the components according to the invention. The concentrations of the components in the supplement may be used to  
20 "top up" the levels in the animal's diet or foodstuff. This can be done by including a quantity of the supplement with the animal's diet or by additionally feeding the animal a quantity of the supplement. The supplement can be formed as a foodstuff with extremely high levels of one or more components of the invention which requires dilution before feeding to the animal. The supplement may be in any form, including  
25 solid (e.g. a powder), semi-solid (e.g. a food-like consistency/gel), a liquid or alternatively, it may be in the form of a tablet or capsule. The liquid can conveniently be mixed in with the food or fed directly to the animal, for example via a spoon or via a pipette-like device. The supplement may be high in one or more components of the

invention or may be in the form of a combined pack of at least two parts, each part containing the required level of one or more component.

5 Preferably the vitamin E is incorporated into a commercial petfood product or a commercial dietary supplement. The petfood product may be a dry, semi-dry, a moist or a liquid (drink) product. Moist products include food which is sold in tins or foil containers and has a moisture content of 70 to 90%. Dry products include food which have a similar composition, but with 5 to 15% moisture and presented as biscuit-like kibbles. The diet, foodstuff or supplement is preferably packaged. In this way the  
10 consumer is able to identify, from the packaging, the ingredients in the food and identify that it is suitable for the dog or cat in question. The packaging may be metal (usually in the form of a tin or flexifoil), plastic, paper or card. The amount of moisture in any product may influence the type of packaging which can be used or is required.

15 The foodstuff according to the present invention encompasses any product which a dog or cat may consume in its diet. Thus, the invention covers standard food products, as well as pet food snacks (for example snack bars, biscuits and sweet products). The foodstuff is preferably a cooked product. It may incorporate meat or animal derived  
20 material (such as beef, chicken, turkey, lamb, blood plasma, marrowbone etc, or two or more thereof). The foodstuff alternatively may be meat free (preferably including a meat substitute such as soya, maize gluten or a soya product) in order to provide a protein source. The product may contain additional protein sources such as soya protein concentrate, milk proteins, gluten etc. The product may also contain a starch  
25 source such as one or more grains (e.g. wheat, corn, rice, oats, barely etc) or may be starch free. A typical dry commercial dog and cat food contains about 30% crude protein, about 10-20% fat and the remainder being carbohydrate, including dietary fibre and ash. A typical wet, or moist product contains (on a dry matter basis) about 40% fat, 50% protein and the remainder being fibre and ash. The present invention is

particularly relevant for a foodstuff as herein described which is sold as a diet, foodstuff or supplement for a cat or dog.

In the present text the terms "domestic" dog and "domestic" cat mean dogs and cats, in particular *Felis domesticus* and *Canis domesticus*.

5

The level of plasma vitamin E in a cat or dog can easily be determined. A representative example of determining plasma vitamin E level is described in the introductory portion of the examples.

10 The concentration of vitamin E in a product (solid or liquid or any other form) can easily be determined. This is also described in the introductory portion of the examples.

15 In the first aspect of the invention, the control diet may, instead, provide a total vitamin E to the animal of 15IU/400kcal.

Preferably, the administration of the vitamin E according to the first aspect of the invention is at a level of from 25IU/400kcal diet. Throughout this text, references to concentrations per kcal are to kcal total metabolisable energy intake. The  
20 determination of calorie density can be identified using Nutritional Requirements of Dogs (1985) National Research Council (U.S.) National Academy Press Washington DC, ISBN: 0-309-03496-5 or Nutritional Requirements of Cats (1986) National Research Council (U.S.) National Academy Press Washington DC, ISBN: 0-309-03682-8. Preferred levels for cats are from 30IU/400kcal, from 35IU/400kcal, from  
25 40IU/400kcal, from 45IU/400 kcal, from 50IU/400 kcal, from 55IU/400kcal, up to about 100IU/400kcal or above. Preferred levels for dogs are from 30IU/400kcal, from 40IU/400kcal, from 45IU/400kcal, from 50IU/400kcal, from 55IU/400kcal, from 60IU/400kcal, from 65IU/400kcal, up to about from 100IU/400kcal or above.

For the first aspect of the invention, the method may include the administration of an amount of vitamin C (ascorbic acid).

5 Vitamin C is a water-soluble substance. It is synthesised *de novo* in both the domestic cat and the domestic dog. Because it is synthesised *in vivo*, the effect of vitamin C supplements in dog and cat has not previously been investigated. In particular, the effect of vitamin C supplementation in cat and dog, as a potential antioxidant and in combination with vitamin E supplementation has not been investigated.

10 The present invention shows that vitamin C levels in a cat or a dog can be increased by supplementation. This is demonstrated by an increase in plasma values following vitamin C supplementation. The increase in vitamin C levels can contribute to a reduction in free radicals and therefore a reduction in oxidative stress in the animal.

15 The vitamin C according to the first aspect of the invention may be in any form. It may be liquid, semi-solid or solid. Preferably it is a heat stable form such as a form of calcium phosphate.

20 The source of the vitamin C is not limiting. Preferred vitamin C sources include crystalline ascorbic acid (optionally pure), ethylcellulose coated ascorbic acid, calcium phosphate salts of ascorbic acid, ascorbic acid-2-monophosphate salt or ascorbyl-2-monophosphate with small traces of the disphosphate salt and traces of the triphosphate salt, calcium phosphate, or for example, fresh liver.

25 The level of vitamin C in a product (solid, liquid or any other form) can easily be determined. This is described in the introductory part of the examples.

30 A further useful point in relation to the use of vitamin E in combination with vitamin C is their potential to act synergistically. This may be assisted by the fact that vitamin E is lipid soluble and vitamin C is water-soluble. Alpha-tocopherol is known to sit in

the lipid membrane. Ascorbate and alpha-tocopherol, for example, interact at the interface between cell membranes or lipoproteins and water. Ascorbic acid rapidly reduces alpha-tocopherol radicals in membranes to regenerate alpha-tocopherol. The preferred concentration of vitamin C according to the first aspect of the invention is a level which preferably increases the plasma vitamin C level of an animal by up to about 25% (preferably 25% or more) in comparison with when the animal is fed a control diet, such that its total vitamin C consumption is (for both a cat or a dog) 5mg/400kcal diet. Levels of vitamin C which do not achieve this increase are still covered by the first aspect of the invention. Levels of vitamin C according to the first aspect of the invention include from 10, 12, 15, 17, 20, 22, 25, 27, 30, 32, 38, 40, 42, 48 up to about 50 mg/400kcal diet. Preferred levels for the cat are the above options from 10 to 48 mg/400kcal and for the dog, the above options from 12 to 50 mg/400kcal. Levels above 55 mg/400kcal provide no added benefit and are usually best avoided.

The first aspect of the invention may include the administration of an amount of taurine. The taurine may be in addition to, or instead of, the supplemented vitamin C described above.

Taurine is an unusual amino acid found in a wide variety of animal species. Taurine is an essential nutrient for the cat which, unlike the dog, is unable to synthesise taurine from precursor amino acids. It is thought that taurine protects cellular membranes from toxic components including oxidants. The increase in vitamin taurine levels in an animal diet can contribute to a reduction in free radicals and therefore a reduction in oxidative stress in the animal, in particular in combination with the other components of the invention.

The taurine according to the first aspect of the invention may be in any form. It may be powdered, crystalline, semi-solid or liquid.

The source of the taurine is not limiting. Preferred taurine sources include aminoethylsulfonic acid ( $C_2H_7NO_3S$ ). Sources may be natural or synthetic.

5 Suitable concentrations of taurine for use according to the first aspect of the invention are usually determined, to some extent as to the processing of the product (for example, whether the product is dry or canned). To maintain plasma taurine levels in the cat at the normal range ( $>60\mu\text{mol/l}$ ), a canned (moist) diet must supply at least 39mg of taurine/kg body weight per day and a dry diet at least 19mg/kg body weight per day. The first aspect of an invention provides, for a product which is not subjected  
10 to a high temperature method (such as canning) a preferred level of from about 80mg/400kcal, more preferably from about 100, increasing even more preferably from 120, 150, 180, 200, 220, 250, 280, 300, 320, 350, 400 and above in mg/400kcal diet. In a product which is processed such as by high temperature, levels according to the invention are preferably from about 380mg/400kcal, more preferably from about 400,  
15 increasing even more preferably from 420, 450, 480, 500, 520, 550, 580, 600, 620, 650, 700 and above in mg/400kcal diet.

The concentration of taurine in a product (solid liquid or in any other form) can be easily determined. A representative method is described in the introductory portion of  
20 the examples. The *in vivo* feline status of taurine can be enhanced through dietary supplementation. The dose response effect of dietary taurine content can be measured by plasma levels. This is also described in the introductory portion of the examples.

The first aspect of the invention may further include the administration of an amount  
25 of a carotenoid. The carotenoid may be in addition to, or instead of, the supplemented vitamin C and/or the taurine as described above.

The carotenoids are a group of red, orange and yellow pigments predominantly found in plant foods, particularly fruit and vegetables, and in the tissues of animals which eat  
30 the plants. They are lipophilic compounds. Some carotenoids act as a precursors of



vitamin A, some cannot. This property is unrelated to their antioxidant activity. Carotenoids can act as powerful antioxidants. Carotenoids are absorbed in varying degrees by different animal species. Carotenoids may be classified into two main groups; those based on carotenes and those based on xanthophylls (which include oxygenated compounds). Common carotenoids include; beta-carotene, alpha-carotene, lycopene, lutein, zeaxanthin and astaxanthin. Carotenoids are not proven to be essential nutrients in the feline or canine diet. Unlike humans and dogs, the cat is unable to convert the precursor beta-carotene into the active vitamin A form since the required enzyme necessary for this conversion is absent from the intestinal mucosa in cats (they do not possess the dioxygenase enzyme which is needed to cleave the carotene molecule).

This invention shows that carotenoids can be absorbed by the domestic cat and dog (to give an increased plasma concentration) and can contribute to a reduction in oxidative stress. Further, the present invention has demonstrated that the carotenoids can be absorbed following their incorporation into a commercial product. As mentioned above, the components of the first aspect of the invention may act synergistically. Vitamin E is able to protect beta-carotene from oxidation and may have a sparing effect on beta-carotene. Vitamin E is thought to protect the chemical bonds of beta-carotene from being oxidised.

The source of the carotenoids is not limiting and can include natural and synthetic sources. In particular, the preferred source is a natural source and includes; marigold meal and lucerne meal (sources of lutein); tomato meal, red palm oil, tomato powder, tomato pomace/pulp (sources of beta-carotene and lycopene). Sources include oils high in carotenoid levels and pure manufactured carotenoids such as lutein, violaxanthin, cryptoxanthin, bixin, zeaxanthin, apo-EE (Apo-8-carotenic acid ethylester), canthaxanthin, citranaxanthin, achinenone, lycopene and capsanthin. Preferred levels of total carotenoids are from 0.01mg/400kcal, or from 0.2mg/400kcal or from 1mg/400kcal or from 2mg/400kcal.

The concentrations of the following carotenoids are preferably:

Beta-carotene: 0.01 to 1.5mg/400kcal, preferably 0.5 to 1mg/400kcal

Lycopene: 0.01 to 1.5mg/400kcal, preferably 0.5 to 1mg/400kcal

5 Lutein: 0.05 to 1.5mg/400kcal, preferably 0.5 to 1mg/400kcal.

In particular, the present invention provides for a combination of carotenoids in the first aspect of the invention.

Preferred sources of the combined carotenoids include;

10 Red Palm Oil and Marigold Meal

Tomato Powder, Marigold Meal and Lucerne

Tomato Pomace and Marigold Meal.

As described above, the invention includes vitamin E and optionally other  
15 components. Useful combinations of the components (preferably in a canned or dry petfood) include;

Vitamin E, vitamin C, taurine, red palm oil and marigold meal

Vitamin E, vitamin C, taurine, tomato powder, marigold meal and lucerne

20 Vitamin E, vitamin C, taurine, tomato powder and marigold meal

Vitamin E, vitamin C, taurine, tomato powder and lucerne

Vitamin E, taurine, tomato pomace and marigold meal.

A combination of the present invention is;

25

Approx. active component

mg/400kcal after production (Dry Product)

Vitamin C 20mg ascorbic acid

Vitamin E 50 IU

30 Taurine 200mg (500 mg in wet product)

Lutein	0.17mg
Lycopene	0.03mg
Beta-carotene	0.01mg

5

A further useful combination of the present invention is:

	Vitamin E	50IU/400kcal
	Vitamin C	20mg/400kcal
10	Taurine	500mg/400kcal
	Beta-carotene	0.5 to 1mg/400kcal
	Lycopene	1mg/400kcal
	Lutein	0.5 to 1mg/400kcal

15 Other useful components of the foodstuff according to the invention, include; trace minerals (not direct antioxidants, but function as cofactors within antioxidant metalloenzyme systems), selenium (an essential part of the antioxidant selenoenzyme, glutathione peroxidase), copper, zinc and manganese (forming an integral part of the antioxidant metalloenzymes Cu-Zn-superoxide dismutase and Mn-superoxide  
20 dismutase.

In accordance with the method of the first aspect of the invention, the components may be administered, or consumed, simultaneously, separately, or sequentially.

25 In accordance with a second aspect of the invention, there is provided a dog or cat foodstuff which delivers to said animal, a concentration of ingredients sufficient to increase the antioxidant status of the animal.

All preferred features of the first aspect of the invention also apply to the second. In particular all of the levels and preferred levels (including more preferred and most preferred levels) according to the first aspect also apply to the second.

- 5 Preferably, the dog or cat foodstuff provides an antioxidant status of greater than 20mg/l of vitamin E.

10 A third aspect of the invention provides a dog or cat foodstuff which provides a concentration of vitamin E at a level according to the first aspect of the invention. The concentration may be as stated according to the first aspect of the invention which provides the described percentage increases or the particular (including preferred) levels.

15 The dog or cat foodstuff according to the third aspect may also provide a concentration of vitamin C at a concentration also according to the vitamin C levels of the first aspect of the invention.

20 The dog or cat foodstuff of the third aspect may provide, in addition, or as an alternative to the vitamin C, a concentration of taurine at a concentration also according to the taurine levels of the first aspect of the invention.

25 The dog or cat foodstuff according to the third aspect may provide, in addition to the vitamin C and/or the taurine or as an alternative, a concentration of a carotenoid at a concentration also according to the carotenoid levels of the first aspect of the invention.

Preferred features of aspects one and two, also apply to the third aspect.

A fourth aspect of the invention provides a dog or cat foodstuff according to the third aspect of the invention, for use in the prevention or treatment of low antioxidant status in a dog or cat.

- 5 Preferred features of aspects one to three also apply to the fourth aspect.

10 A fifth aspect of the invention provides a dog or cat foodstuff according to the second, third, fourth or ninth aspects of the invention, for use in the prevention or treatment of any disorder which has a component of oxidative stress. The use is separately for the prevention or treatment of oxidative stress as a component of a "disease" or "disorder" (thus the disease or disorder may be reduced by alleviating (at least to an extent) a component of oxidative stress). Such disorders include; ageing, cancer, heart disease, atherosclerosis, arthritis, cataracts, inflammatory bowel disease, renal disease, renal failure, neurodegenerative disease and immunity (such as compromised immunity).  
15 Also included are prevention and treatment of oxidative stress caused by animal vaccinations (often annually) and anaesthetics, which may also be used for annual procedures such as dental treatments (which may require general anaesthetic) and exposure to UV light or radiation. With respect to immune function, this is equally applicable to those subjects who have a compromised immune function due to age  
20 (e.g. growing animals or senescing animals) as well as those experiencing immunological challenge. The maintenance of a healthy immune response (as well as optimising or boosting an immune response) in animals who are clinically healthy is also included in this definition.

25 The immune system of vertebrate animals is much discussed in the art (for example "Immunology" by Roitt, Brostoff and Male, Gower Medical Publishing, London, New York, 1985). Immunological challenge includes infection, vaccination and other external factors such as anaesthesia (for example prior to surgery). It is an object of the present invention to provide a diet/foodstuff or supplement (and related aspects)  
30 which can be used to maintain, optimise or "boost" the immune system such that an

improved immune response is given on an immunological challenge. An immune response can be monitored by measuring antibodies produced in response to a given antigen. Such knowledge and technology is standard in the art. An improved immune response may be represented by a higher level (titre) of circulating antibodies within a given time frame, a faster detected antibody response or maintenance of the circulating antibody titre for a longer period of time.

An improved immune response assists the animal during an immunological challenge and can be particularly useful for young animals, since young animals may not have a fully developed immune system. As young animals are often vaccinated, the present invention provides means by which an improved immune response can be given by the animal when vaccinated. The present invention is particularly useful for feeding to a dog prior to vaccination with vaccine antigens for distemper, parvovirus and/or adenovirus. The present invention is particularly useful for feeding to a cat for vaccines or a combined vaccine against Feline Panleucopenia, Feline Calicivirus and/or Feline Herpesvirus. The length of time suitable for feeding prior to immune challenge depends on the animal in question and the immunological challenge. The foodstuff can be fed consistently. Periods of 8, 6, 4, 2 and 1 week prior to immune challenge are suitable. Longer periods are also suitable.

The present invention also provides a method (suitable for a dog or a cat) for preventing or treating a component of oxidative stress or a disorder which has a component of oxidative stress, said method comprising feeding said dog or cat a foodstuff according to the present invention. The disorders are as described above. The invention also relates to a method for strengthening an immune response, in a dog or cat, to an immunological challenge, said method comprising feeding a foodstuff according to the present invention.

Preferred features of aspects one to four also apply to the fifth aspect.

A sixth aspect provides for the use of vitamin E, in the manufacture of a medicament/clinical or veterinary diet for the prevention or treatment of any cat or dog disorder which has a component of oxidative stress, or for the prevention or treatment of oxidative stress.

5

Preferred features of aspects one to five also apply to the sixth.

A seventh aspect of the invention provides for the use of vitamin E at a level of 25IU/400kcal or above, incorporated into a foodstuff as an *in vivo* antioxidant, in a dog or a cat. All preferred features of aspects one to six also apply to the seventh. In particular, the levels of vitamin E may be as the preferred levels for vitamin E set out for the first aspect of the invention.

10

An eighth aspect of the invention provides a method for making a foodstuff according to any of the second to fifth aspects of the invention the method comprising mixing together at least two ingredients of the foodstuff. One of the components will be the required level of vitamin E. The preferred form of the foodstuff is a petfood product and therefore the method for making the petfood product, in any form, comprises mixing together the ingredients for the petfood product and incorporating one or more of the components according to the invention. The components may be added at any time during the manufacture/processing of the foodstuff, including at the end, as the last step before packaging.

15

20

The product can be made according to any method known in the art, such as in Waltham Book of Dog and Cat Nutrition, Ed. ATB Edney, Chapter by A. Rainbird, entitled "A Balanced Diet", pages 57 to 74, Pergamon Press.

25

A ninth aspect of the invention provides a dog or cat foodstuff comprising vitamin C at a concentration of from 15mg/400kcal diet. The diet, foodstuff or supplement details are as those described for the previous aspects of the invention in relation to the

30

vitamin C component to the extent that it comprises a vitamin C concentration of from 15 mg/400kcal diet. Features of aspects one to eight, as herein described may be individual or combined options together with the vitamin C concentration according to the ninth aspect of the invention. The ninth aspect of the invention provides a  
5 foodstuff useful for the prevention or treatment of a disorder which has a component of oxidative stress. Such disorders are also those as described above for the previous aspects of the invention. The inclusion of vitamin C in a dog or cat foodstuff is unique in as far as it relates to the concentrations of vitamin C stated and in particular or for the uses given.

10

The vitamin C concentrations range from 15mg/400kcal upwards. Preferred levels are those above 15mg/400kcal as set out above according to the preferred concentrations of vitamin C according to the first aspect of the invention. Because vitamin C is synthesised *in vivo* in both the domestic cat and the domestic dog it has never been of  
15 particular interest to consider introducing to a cat or dog supplemental levels of vitamin C via cat or dog food. However, the present invention shows that such a diet can be particularly useful, primarily for the production of a clinical diet/veterinary diet/medicament.

20

The present invention also provides for the use of vitamin C in a foodstuff for a dog or a cat. The use may be in the manufacture of a diet for the prevention or treatment of a disorder which has a component of oxidative stress or for the prevention or treatment of the oxidative stress component. Those disorders include cancer, ageing, heart disease, atherosclerosis arthritis, cataracts inflammatory bowel disease, renal disease,  
25 renal failure, neurodegenerative disease or compromised immunity, for example, an animal suffering from an infection. The present invention may also be used to treat or assist in the event of an immunological challenge in healthy animals.

30

The present invention also relates to a method for the prevention or treatment, in a dog or cat, of a disorder which has a component of oxidative stress (or of the oxidative



stress component) comprising feeding to said cat or dog a foodstuff according to the ninth aspect of the invention.

The following figures are referred to in the examples section:

5

Fig. 1, which shows an increase in vitamin E plasma status in dogs through supplementation with 50IU/400kcal and 100IU/400kcal of vitamin E.

10

Fig. 2, which shows vitamin C plasma status in cats, reflecting dietary vitamin C supplementation.

Fig. 3, which shows vitamin E plasma status in cats with dietary vitamin E supplementation.

15

Figs. 4 and 5, which show levels of anti-parvovirus antibody titres with supplemented and unsupplemented diets, post vaccination.

Fig. 6, which shows an anti-distemper vaccine response with supplemented and unsupplemented diets, post vaccination.

20

Fig. 7, which shows maintenance of anti-adenovirus antibody titres in dogs supplemented with an antioxidant cocktail.

25

Fig. 8, which shows the measurement of FRAP in dogs fed an antioxidant diet for 8 weeks.

Fig. 9, which shows plasma vitamin E levels in dogs fed an antioxidant diet for 8 weeks.

The invention will now be described with reference to the following non-limiting examples. Those skilled in the art will recognize that variations of the invention embodied in the examples can be made, especially in light of the teachings of the various references cited herein, the disclosures of which are incorporated by reference.

## EXAMPLES

### Introductory Portion

This section describes, firstly, how blood samples may be taken for determination of vitamin E, vitamin C, taurine and carotenoids. Also described are methods for analysis of components in plasma and methods for measuring components in food. In addition to the details set out below, details regarding analytical procedures can be found in McDowell L.R. (1989) Vitamin E: In Vitamins in Animal Nutrition Chapter 4, page 96, Academic Press, UK.

### Plasma and Whole Blood Taurine

#### Preparation of samples:

Blood samples are collected into heparinarised bottles from either the cephalic or jugular vein. Following mixing of the sample on a roller, the samples are kept on ice for transfer to the laboratory. Whole blood is then frozen at  $-20^{\circ}\text{C}$  until analysis. Alternatively for plasma measurement, plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at  $0^{\circ}\text{C}$ ). Plasma is frozen at  $-20^{\circ}\text{C}$  until analysis.

The analysis of Taurine in cat plasma/blood is carried out by taking the sample and precipitating out protein by reaction with sulpho-salicylic acid solution. The sample is then centrifuged and the supernatant liquor filtered.

#### Reference where plasma taurine has been measured in cats:

Earle, K.E. and Smith, P.M. (1991) The effect of dietary taurine content on the plasma taurine concentration of the cat. British Journal of Nutrition 66, 227-235.

### Plasma Vitamin C

#### Preparation of samples:

Blood samples are collected into heparinarised light-protected (foil-wrapped) bottles from either the cephalic or jugular vein. Following mixing of the sample on a roller, the samples are kept on ice for transfer to the laboratory. Plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at 0°C). Plasma is frozen at -20°C until next-day analysis. Samples are prepared under subdued lighting at all times.

1ml plasma extracted with 5ml extractant (15g metaphosphoric acid + 0.475g EDTA + 20ml glacial acetic acid in 500ml water) – the procedure is then the same as for product.

A preferred minimal dose of vitamin C to achieve an increase in plasma in cats is 20mg/400kcal. A preferred minimal dose of vitamin C tested to achieve an increase in plasma in dogs was 27mg/400kcal.

### Plasma Vitamin E

#### Preparation of samples:

Blood samples are collected into heparinarised bottles from either the cephalic or jugular vein. Following mixing of the samples on a roller, the samples are kept on ice for transfer to the laboratory. Plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at 0°C). Plasma is frozen at -20°C until analysis.

Sample size = 250µl. The sample is extracted into hexane after the addition of tocopherol acetate as internal standard. The hexane is evaporated and the residue dissolved in methanol and injected onto the HPLC. Separation is achieved using a reverse-phase column with methanol as eluent with UV detection at 285nm.

A preferred minimal dose of vitamin E to achieve an increase in plasma in cats is 34 IU/400kcal. A preferred minimal dose of vitamin E tested to achieve an increase in plasma in dogs was 50IU/400kcal.

5     Carotenoid determination in plasma

Blood samples are collected into heparinarised light-protected (foil-wrapped) bottles from either the cephalic or jugular vein. Following mixing of the samples on a roller, the samples are kept on ice for transfer to the laboratory. Plasma is extracted by centrifugation of blood samples (at 3500 rpm for 10 minutes at 0°C). Plasma is frozen  
10    at -80°C until analysis. Samples are prepared under subdued lighting at all times.

The following two methods may be used to determine carotenoid concentration in plasma.

15    Method 1

The first method is to measure the major carotenoids of interest, with the exception of lutein and zeaxanthin which will not be separated using this method.

The method used to detect carotenoids is a variation of that of Craft, N.E. and Wise, S.A., Journal of Chromatography, 589, 171-176, (1992).  
20

The extraction of carotenoids from plasma is achieved using a variation of that of Thurnham *et. al.* Clinical Chemistry, 34, 377-381, 1988.

25    Method 2

The second method is to separate lutein and zeaxanthin and to separate the different isoforms of the carotenoids.

The method used to detect the carotenoids is a variation of that of Yeum, Kyung-Jin.,  
30    *et. al.* Am. J. Clin. Nutr, 64, 594-602, 1996.

The extraction of carotenoids from plasma is achieved using a variation of that of Thurnham *et. al.* Clinical Chemistry, 34, 377-381, 1988.

- 5 All extractions were carried out under subdued lighting, and all stock solutions of carotenoids were stored under argon.

#### Vitamin C – Food Product

- 10 Ascorbic acid is enzymatically oxidised to dehydro ascorbic acid which is condensed with o-phenylene diamine to the fluorescent quinoxaline derivative. The latter is separated from interfering compounds by reversed-phase HPLC with fluorimetric detection.

#### Vitamins A & E Food Product

- 15 The sample is hydrolysed with ethanolic potassium hydroxide solution and the vitamins extracted into petroleum ether. The petroleum ether is removed by evaporation and the residue is dissolved in propan-2-ol. The concentration of vitamin A and E in the propan-2-ol extract is determined by reversed-phase liquid chromatography.

20

#### Free Taurine – Food Product

Free Taurine is that which is nutritionally available in a product.

- 25 The analysis of Free Taurine is carried out by taking the sample, adding dilute Hydrochloric acid. This is then macerated and transferred to a volumetric flask. A small amount is then taken and sulpho-salicylic acid is added to precipitate the protein. The sample is then centrifuged and the supernatant liquor filtered. The resulting solution is reacted with dansyl chloride and analysed by HPLC using fluorescence detection.

30

#### Carotenoids – Food Product

20-25g sample taken for analysis. Sample is saponified with 28% ethanolic potassium hydroxide for 30mins. At 90°C under nitrogen and with pyrogallol as antioxidant. After cooling, the saponified extract is extracted with 2x250ml mixed ethers (pet.  
5 Ether/diethyl ether 1:1) and the organic phase is washed with water until neutral. The ether extract is evaporated at 35°C under vacuum with BHT as antioxidant and the residue redissolved in the HPLC mobile phase. The carotenoids are determined using reverse phase HPLC using UV detection at 450nm.

10 In addition to the experimental work given, the invention was an indicator of improved health by decreasing the osmotic fragility of cat erythrocytes following feeding of the antioxidant cocktail to cats.

The ability of red blood cells (erythrocytes) to withstand osmotic stress was tested.  
15 The method involved re-suspension of washed erythrocytes in solutions with different NaCl concentrations; these are incubated and then centrifuged. Haemoglobin is released from the cells according to their osmotic fragility. Results showed that erythrocytes of cats fed antioxidant cocktails of the invention showed a greater resistance against osmotic stress as significant lower concentrations of NaCl were  
20 required to induce the same level of heamolysis. The ability of erythrocytes to tolerate situations of osmotic stress is an indicator of an improved physiological status.

#### Example 1

##### Vitamin E

25

A group of 8 dogs were maintained a nutritionally complete diet (see reference section representative diet) for a period of 6 weeks prior to receiving one of the two supplementary levels of vitamin E (alpha-tocopherol acetate below (table 1)).

Table 1: Vitamin E content in test diet before supplementation

Diet	Vitamin E content before Supplementation
Complete and balanced	8.7 IU/400kcal

Plasma levels significantly ( $p < 0.05$ ) increased following only 1 week of supplementation at both the 50IU/400kcal and 100IU/400 kcal level.

- 5 Plasma saturation appeared to occur after 1 week of supplementation. Plasma levels declined to baseline levels after 2 weeks of stopping supplementation.

It can be concluded from the doses studied, that dietary supplementation with vitamin E significantly increases plasma status in dogs by a magnitude of 60-66% (figure 1).

10

### Example 2

#### Antioxidant Supplementation in Cats

#### Vitamin C

- 15 4 groups of 8 or 9 cats were given oral supplements of vitamin C at 4 different levels whilst being maintained on a nutritionally complete diet (see reference diet section).

Baseline plasma vitamins C levels demonstrate that there are no significant differences between the groups prior to supplementation.

20

As can be seen in figure 2, within 7 days the plasma vitamin C levels for all 4 groups significantly increased above their baseline prior to supplementation.

- 25 Although the higher vitamin C supplements resulted in greater plasma values, the increase was not significantly different between the 4 groups.

Following the end of the supplementation period plasma vitamin C levels returned to baseline.

These data demonstrate that the antioxidant status of cats can be increased with vitamin C supplementation of their diet at relatively low levels.

### Example 3

#### Vitamin E

The impact of typical dietary vitamin E levels on the vitamin E status of cats has been evaluated, as well as the effect of dietary supplementation.

The plasma vitamin E concentrations of 2 groups of 12 cats maintained on 2 commercial nutritionally complete cats diets (see reference diet section) with different dietary vitamin E levels were determined. The plasma levels (duplicate measurements 2 weeks apart) seen in Table 2 demonstrate that cats maintained on a diet for a period of 4 weeks with a higher vitamin E level have a relatively increased vitamin E status.

Table 2: Vitamin E plasma status in cats reflecting vitamin E intake

Vitamin E content	Plasma Vitamin E ( $\pm$ SD) ug/ml
60IU/400kcal	26.62 $\pm$ 7.2
24IU/400kcal	15.09 $\pm$ 4.0

In order to determine the effect of supplementation, oral vitamin E supplements ( $\alpha$ -tocopherol acetate) were administered to a group of 12 cats whilst being maintained on the nutritionally complete diet.

The effect of the supplementation can be seen in figure 3. Plasma vitamin E levels



were significantly increased following supplementation, reaching saturation after approximately 4 to 6 weeks of supplementation.

Hence, dietary vitamin E supplementation can enhance the antioxidant status of cats.

5

#### Example 4

Total plasma antioxidants in cats; normal ranges and influence of age.

10 The total antioxidant status in the domestic cat has never previously been reported. The aim of this study was to validate a method of determining total antioxidant status in the cat, determine normal total antioxidant ranges in healthy adult cats and investigate the effect of age on total plasma antioxidant status.

15 A colorimetric assay kit (NX2332) manufactured by Randox Laboratories Limited, was validated for the determination of total antioxidant status in the cat. Assay precision was determined both by replicate analysis of cat plasma samples, and of commercial quality control (QC) material (PAR 721013 and PAR 721014; Bio-stat Diagnostics), Intra and Inter assay coefficient of variation (CV) demonstrated acceptable variation for spectrophotometric assays with plasma sample CV < 10%, and QC CV < 5%. Dilution of cat plasma produced a linear response in the assay.

25 The effect of ageing on plasma antioxidant levels was evaluated. 134 cats, maintained on a range of nutritionally complete cat foods (see diet reference section), participated in the study. Total antioxidant status was evaluated in single plasma samples from 69 male and 65 female domestic shorthaired cats aged between 6 months and 14 years. All means are quoted  $\pm$  the standard deviation (SD).

The results indicate the presence of a transitional period of antioxidant status occurring at approximately 6 years of age. A Newman-Keuls multiple range test showed that the

total plasma antioxidant status of cats aged under 6 years was significantly ( $p<0.01$ ) higher than those aged over 6.5 years (see Table 3). It is not known whether a decline in antioxidant status at this age signals a greater susceptibility to illness or whether antioxidant status in this age influences lifespan in cats.

5

Table 3. Mean total plasma antioxidant concentrations from cats categorised according to age.

Age Category (years)	Total Plasma Antioxidant Status (mmol/l) $\pm$ SD	Number of animals
<6	$0.920 \pm 0.77^a$	47
6	$0.872 \pm 0.182^{ab}$	9
>6	$0.799 \pm 0.092^b$	78

*Superscript denote homogeneous groups*

10

#### Example 5

Total plasma antioxidant and superoxide dismutase status in dogs

15

Little is known about the antioxidant status in the domestic dog. The aim of this study was to validate a method of, and determine normal ranges of, total plasma antioxidants (TPAO) and erythrocyte SOD (superoxide Dismutase) activity in the dog.

20

Colorimetric assay kits manufactured by Randox laboratories Limited were validated for determination of TPAO status (Kit No: NX2332 and SOD status (Kit No: SD 125 in the dog. For TPAO, assay precision was determined both by replicate analysis of dog plasma samples, and, of commercial quality control (QC) material (PAR 721013 and PAR 721014: biostat Diagnostics). Inter and Intra assay coefficient of variation (CV) demonstrated acceptable variation for spectrophotometric assays, with plasma sample  $CV<10\%$  and  $QC<5\%$ . SOD status assay precision was determined by

replicate analysis of dog erythrocyte samples. Inter and Intra assay coefficient of variation (CV) demonstrated acceptable variation for spectrophotometric assays with erythrocyte sample CV<10%.

5 TPAO and erythrocyte SOD status were evaluated in 30 male and 20 female dogs aged between 9 months and 16 years. Ten breeds were represented. All dogs were clinically normal, and had been maintained long-term on a variety of manufactured nutritionally complete diets. There was no apparent relationship between age and TPAO or SOD activity. Dogs were not equally represented across the age groups  
10 (data not shown), and further work is in progress to assess whether this observation is supported by a larger sample size and better age spread. No significant difference was seen between the gender for either mean TPAO status (male:  $0.719 \pm 0.135$ , female:  $0.786 \pm 0.101$ ) or SOD activity (male:  $1275.41 \pm 264.46$ , female:  $1267.61 \pm 166.34$  U/g Hb). However, Bartlett's Test showed a significant difference ( $p < 0.05$ ) between  
15 variance of SOD activity in male (6994.0) and female (27670.3) dogs.

Analysis of those breeds with five or more representatives showed a significant difference ( $p < 0.01$ ) for both SOD activity, and TPAO status, between breed but not gender. Newman-Keuls multiple range tests showed Beagles to have significantly  
20 lower mean SOD activity ( $p < 0.05$ ) and mean TPAO status ( $p < 0.01$ ) than Labradors and Yorkshire Terriers, Table 4.

Table 4. Superoxide dimutase and total plasma antioxidant activity for three breeds of dog.

Breed	Mean SOD activity $\pm$ SD	Mean TPAO activity $\pm$ SD	n
Beagle	$1084.70 \pm 136.24^a$	$0.569 \pm 0.094^a$	10
Labrador	$1323.65 \pm 185.77^b$	$0.830 \pm 0.113^b$	15

Yorkshire Terrier	1293.76±215.54 <sup>b</sup>	0.798±0.036 <sup>b</sup>	5
-------------------	-----------------------------	--------------------------	---

*Superscripts denote homogeneous groups within columns (Newman-Keuls multiple range test)*

*n=number of animals*

- 5 These data indicate that it may not be sufficient to assume a single value for normal SOD and TPAO ranges in dogs. In this instance two values are required, one for Beagles and one for the other two breeds. The 95% confidence intervals for the mean ranges of TPAO status and erythrocyte SOD activity in Beagles are  $0.569 \pm 0.067$  mmol/l and  $1084.9 \pm 97.27$  U/g Hb respectively, and for the other two breeds;  $0.822 \pm$   
 10  $0.047$  mmol/l and  $1316.2 \pm 88.03$  U/g Hb.

#### Example 6

Assessment of total antioxidant status in the cat and dog using a fully automated colormetric assay

15

- The aim of this study was to validate a colormetric assay kit, manufactured by Randox Laboratories Ltd, for the determination of total antioxidant status in the cat and dog. Secondly the validated assay was used to assess changes in total antioxidant status of the cat and dog with age and to compare these changes in other biochemical and  
 20 haematological parameters. The assay reacts 2,2'-Azino-di-(3-ethylbenzthiazoline sulphonmate) (ABTS) with a peroxide and  $H_2O_2$  to produce a radical cation  $ABTS^+$  which can be measured to 600nm. Antioxidants present in a sample will cause suppression of this colour production to a degree proportional to their concentration. The assay was performed on a Cobas Mira analyser (Roche Diagnostics) using the  
 25 protocol supplied by Randox Laboratories. Assay precision was determined by replicate analysis of cat and dog plasma samples and of commercial quality control (QC) material. Inter-assay and intra-assay CV were both less than 5% for the QC material and were both less than 10% for the cat and dog plasma samples. Dilutions

of cat and dog plasma produced a linear response in the assay. Routine haematology and biochemistry profiles, including total antioxidant status, were performed on domestic short haired cat and on several breeds of pedigree dogs of various ages. Antioxidant status in the cat increased up to 2 months of age, but then showed a  
5 subsequent decline. No sex difference were apparent. Female dogs of less than 1 year showed a slight decrease in antioxidant status, otherwise there was no significant change with age. Multiple regression analysis demonstrated a relationship between antioxidant status, albumin, asparate aminotransferase and calcium in the cat and antioxidant status, phosphate and alanime aminotransferase in the dog. The validation  
10 results were considered to be acceptable and the assay is suitable for the determination of total antioxidant status in the cat or dog.

#### Example 7

Effect of a vitamin C supplement on plasma status in healthy adult cats.

15 Vitamin C is a major water soluble antioxidant *in vivo*, that can delay or inhibit oxidation, important particularly in extracellular fluids. However the response in the cat (*Felis domesticus*) to different dietary levels of vitamin C has not been previously investigated. The aim of this study was to establish the effect of vitamin C  
20 supplementation in healthy adult cats on plasma status.

Plasma vitamin C concentrations of 33 cats were determined by reversed-phase High Performance Liquid Chromatography. Subsequently the cats were allocated into 4  
25 groups by stratified randomised sampling, ensuring there were no significant differences between the baseline plasma vitamin C levels of the 4 groups (ANOVA  $p > 0.05$ ). Daily vitamin C supplements (crystalline L-ascorbic acid, ICN Pharmaceuticals, UK, in a gelatine capsule, Analytical Supplies Limited, UK) were given orally to the cats for 21 days. The 4 groups of cats received either 3.5, 7.0, 10.5 or 21.0 mg vitamin C/day. Plasma vitamin C levels were determined at 7, 14 and 21 days of  
30 supplementation, as well as, at 21 days post-supplementation. All cats were

maintained on a nutritionally complete canned diet, with a vitamin C content of 11.6 mg/1.6MJ.

5 The plasma vitamin C levels of the cats significantly increased at 7 days after daily supplementation at all 4 dietary levels administered (paired t-test  $p < 0.05$ ), and during the supplementation period these levels were maintained, Table 5. Although the higher dietary supplementation levels of vitamin C achieved greater plasma values when compared with those of the lower dietary levels, there were no significant differences between dietary groups in the plasma increases (repeated measures multifactor ANOVA using General Linear Model  $p < 0.05$ ).  
 10 The plasma levels of all cats returned to baseline levels 21 days post-supplementation.

Table 5. Plasma Vitamin C Concentrations (ug/ml  $\pm$  SD)

Group	n	Time of supplementation (days)				21 days post-supplementation
		0	7	14	21	
1	8	3.93 <sup>a</sup> $\pm$ 0.98	4.73 <sup>b</sup> 0.71	4.73 <sup>b</sup> $\pm$ 0.39	5.02 <sup>b</sup> $\pm$ 0.64	3.66 <sup>a</sup> $\pm$ 0.74
2	8	4.16 <sup>a</sup> $\pm$ 1.18	5.28 <sup>a</sup> $\pm$ 0.99	5.55 <sup>b</sup> $\pm$ 0.67	5.20 <sup>b</sup> $\pm$ 0.82	4.17 <sup>a</sup> $\pm$ 0.73
3	8	4.34 <sup>a</sup> $\pm$ 1.24	5.20 <sup>a</sup> $\pm$ 1.16	5.46 <sup>b</sup> $\pm$ 1.02	5.42 <sup>b</sup> $\pm$ 1.28	4.56 <sup>a</sup> $\pm$ 1.14
4	9	4.41 <sup>a</sup> $\pm$ 0.96	5.91 <sup>b</sup> $\pm$ 1.04	5.90 <sup>b</sup> $\pm$ 0.54	5.85 <sup>b</sup> $\pm$ 0.80	4.17 <sup>a</sup> $\pm$ 0.65

15 Heterogeneous superscripts within rows indicate a significant difference with time (ANOVA  $p < 0.05$ )

These data demonstrate that at low levels of dietary supplementation with vitamin C administered on a daily basis, the plasma status of cats can be significantly enhanced.  
 20 Continual supplementation is required in order to maintain the enhanced plasma status.

#### Example 8

Validation and normal ranges of plasma ceruloplasmin concentration in cats and dogs.

The cuproenzyme, ceruloplasmin has a number of functional roles with the body. As a copper storage protein, ceruloplasmin helps protect against the catalytic ability of free copper ions. Free copper can accelerate autoxidation reactions through single-electron (radical) transfer, as well as react with hydrogen peroxide to form highly reactive hydroxyl radicals which can lead to cellular disruption. At time of trauma, ceruloplasmin also promotes the conversion of iron from its pro-oxidant ferrous form to ferric iron. As an acute phase protein, ceruloplasmin can be indicative of inflammation or infection and thus be used in conjunction with serum ferritin as a measure of iron stores.

A colorimetric method to determine ceruloplasmin oxidase activity in cats and dogs was validated based on the method of Sunderman F.W. and Nomoto, S. (1990) Clin. Chem 16, 903 using p-phenylenediamine as the substrate. Two dog and two cat serum samples were analysed ten times within a single run. Intra-assay coefficient of variation of 1.94% and 2.95% were determined for the dog samples, and 1.81% and 3.94% for the cat. Analysing the same samples on ten separate days, inter-assay coefficients of variation of 8.21% and 7.01% for dog, 6.88% and 9.35% for cat samples were determined. Hence an acceptable level of intra- and inter-assay variability was achieved. Following this, the difference between the ceruloplasmin concentration of serum and plasma samples was evaluated. No significant difference was determined between plasma and serum samples for either species. Hence thereafter plasma samples were collected in order to reduce the total volume of sample required.

In order to establish normal ranges, plasma samples were obtained from 102 healthy dogs (mixed breed, age and sex) and 54 healthy domestic short-haired cats (mixed age and sex). The mean plasma ceruloplasmin concentrations determined for dog and cat were 9.28 IU/L (SD 3.03 IU/L) and 10.90 IU/L (SD 3.34 IU/L) respectively. Using these values, normal ranges (mean  $\pm 2$ SD) of 3.22 IU/L 15.35 IU/L for dogs, and 4.22

IU/L to 17.58IU/L for cats were established. This normal range determined for dogs is consistent with that previously reported (Solter P.F, et al (1991) Am J Vet Res 52, 1738, 1991) A normal range for cats has not been previously established, however its similarity to that of the dog suggests that there is little difference in circulating ceruloplasmin levels between these two species. The normal ranges established during this study may be used to evaluate the health status of cats and dogs.

#### Example 9

Canine ferritin : Assay validation and normal range for serum.

Ferritin plays an important role in the antioxidant defence system with the body. As a high affinity storage protein for iron, ferritin maintains iron in a safely bound form preventing the reactive ferrous ion from participating in Fenton reactions, which can lead to oxidative damage. In normal health ferritin, a species-specific protein, if found in the blood at concentrations that reflect body iron stores and in conjunctions with other parameters can be used to assess *in vivo* iron status. In order to determine circulating ferritin levels in the dog, an enzyme-linked immunoassay (ELISA) was developed, adapted from the method of Weeks, B.R. *et al* (1988) Am J Vet Res 49,1193 (1988) using monoclonal antibodies. Following the assay validation, a normal range for dogs was established.

In the range of 0-40 ng/ml the ferritin standards were linear (least squares regression analysis,  $r=0.997$ ) and the recovery of purified ferritin added to canine sera was 97.7%. The intra-assay coefficient of variations derived from determining the ferritin concentration in two serum samples 12 time were 8.2% and 6.6%. The inter-assay coefficient of variations of two serum samples assayed 10 time on separate days were 16.6% and 16.2%.

Serum samples were obtained from 96 healthy dogs of mixed sex and five different



breeds for ferritin determination in order to establish a normal range. Each sample was assayed either in triplicate or quadruplicate and the mean of these values was used as the ferritin concentration for that sample. The serum ferritin concentrations varied from 67.20 to 621.07 with a mean value of 371.62 ng/ml (SD 102.85 ng/ml). The data was normally distributed. These results demonstrate that serum ferritin can be determined with good repeatability and reproducibility for dogs. The values obtained will be used as a normal range for future studies and may provide a useful method of determining iron storage levels in dogs.

#### 10 Example 10

Supplementation of dietary tocopherol increases canine plasma values outside the normal ranges

Vitamin E is the collective name for 8 naturally occurring molecules, 4 tocopherols and 4 tocotrienols. The biological activity of the various forms roughly correlates with their antioxidant activities with the order of relative peroxy scavenging reactivities of  $\alpha > \beta > \gamma > \delta$ -tocopherol. Generally it is accepted that providing nutrients in excess of the requirement does not deliver any measurable benefit. The minimum requirement for vitamin E in adult dogs has been established as 2.5 IU  $\alpha$ -tocopherol/400kcal diet (Nutrient Requirements of Dogs (1985) National Research Council (U.S.) National Academy Press Washington DC ISBN:0-309-03496-5 ). Prepared petfoods typically contain up to 10 times this amount but across the normal ranges of vitamin E in petfoods, plasma concentrations tend to be constant. In a study to evaluate the impact of supplementary vitamin E on the plasma response, 6 adult dogs, maintained on a nutritionally complete (see diet reference section) canned dog food (vitamin E content 8.2 mg/400kcal (8.2IU/400kcal), were offered a supplement equivalent to 100 IU vitamin E/day for 6 weeks. A control group of 6 dogs was maintained under the same conditions but received no dietary supplement. Plasma  $\alpha$ -tocopherol was monitored during, and for 4 weeks following, the supplementation period.

The plasma  $\alpha$ -tocopherol levels are presented in Table 6. The treatment group had a mean baseline plasma  $\alpha$ -tocopherol level which was not significantly different from the control group ( $p=0.43$ ). Following 2 weeks of supplementation the mean value of the treatment group had significantly increased compared to the control ( $p=0.002$ ) and the baseline value ( $p<0.001$ ). Measurements made on days 56 and 70 (days 14 and 28 post-supplementation) showed levels which remained significantly higher than baseline. These results clearly indicate that dietary vitamin E above the levels typically found in prepared petfoods can elevate plasma status in dogs and that this can be sustained for several weeks following supplementation. In order to saturate plasma it appears that levels greater than those currently found in prepared petfoods may need to be fed. Given the potent antioxidant capacity of vitamin E it may prudent to increase vitamin E status in dogs, in order to maximise the opportunity to prevent free-radical damage and the associated degenerative disease.

Table 6. Plasma response to  $\alpha$ -tocopherol supplementation in healthy dogs

	Baseline	Day 14	Day 28	Day 42	Day 56	Day 70
Test	15.9± 5.91 ♦	3.67±6.65 *	32.6 ±8.39*	35.4±7.07 *	363±7.50 *	28.2±6.8 7*
Control	18.4±5.0 3* ♦	22.2±7.29	19.9±4.00 *	23.2±4.13 *	30.5±7.9 3	23.3±3.7 1*

\* represents homogeneity ( $p>0.05$ ) within the same group

♦ represents homogeneity ( $p>0.05$ ) between the 2 groups

### Example 11

Typical plasma vitamin E ranges in healthy dogs

Vitamin E is a collective name for eight different tocopherols and tocotrienols which share the same biological activity. Of the eight,  $\alpha$ -tocopherol is biologically and chemically the most active form of vitamin E and 1mg  $\alpha$ -tocopherol is equivalent to

1IU of vitamin E. Vitamin E is a potent antioxidant in the body, and it primarily resides in biological membranes where it protects membrane phospholipids from peroxidation damage. Vitamin E also inhibits oxidation of vitamin A and therefore also protects against vitamin A deficiency. The minimum requirement for vitamin E in adult dogs has been established as 2.5 IU  $\alpha$ -tocopherol/400kcal diet (Nutrient Requirements of Dogs (1985) National Research Council (U.S.) National Academy Press Washington DC ISBN: 0-309-03496-5). However, there is a paucity of information as to normal vitamin E plasma values in healthy adult dogs and puppies. In order to determine typical baseline plasma  $\alpha$ -tocopherol levels in healthy adult and puppy dogs, a series of studies were carried out in dogs fed a range of canned and dry nutritionally complete prepared petfoods (see diet reference section), Table 7. Diet was fed in accordance to body weight ( $110 \text{ kcal/kg}^{0.75}$ ). The individual plasma  $\alpha$ -tocopherol levels ranged from 9 to 39.2 mg/l with a median value of 21.1 mg/l. There were no significant differences between the mean baseline  $\alpha$ -tocopherol levels of the groups of dogs maintained on the different diets ( $p=0.24$ ). These data indicate that typical  $\alpha$ -tocopherol levels in puppies and adult dogs are similar and that, within the usual vitamin E levels found in prepared petfoods, plasma tocopherol levels exhibit similar ranges.

Table 7. Diet  $\alpha$ -tocopherol level (IU/400kcal) is shown with the corresponding means plasma  $\alpha$ -tocopherol level (mg/l $\pm$ SD).

Food format	$\alpha$ -Tocopherol content (IU/400kcal)	Plasma $\alpha$ -Tocopherol (mg/l $\pm$ SD)	n
Canned	9.77	21.15 $\pm$ 6.4	20
Dry	6.31	22.72 $\pm$ 6.62	6
Dry	13.76	25.33 $\pm$ 5.12	10

Dry	18	21.56±4.88	23
-----	----	------------	----

### Example 12

Exercise in healthy adult dogs increases plasma TBARS-an indicator of oxidative stress.

5

Plasma TBARS (thiobarbituric acid reactive substances) measured by HPLC with pre-column derivatisation is a well-documented maker of lipid peroxidation *in vivo*. The aim of this present study was to survey the effects of a bout of exercise in dogs (*Canis familiaris*) upon this index of oxidative stress.

10

A panel of 14 dogs of mixed breed and age were maintained on a nutritionally complete commercial dry diet or three months prior to, and throughout the duration of this trial. The extent of lipid peroxidation immediately prior to an following an acute 20 minute bout of paddock exercise was quantified by determining the malonaldehyde (MDA) formed as TBARS. This analysis was measured according to the method described by Bird, R.P. & Draper, H.H. (1984), Methods in Enzymology. 105:299-305 (1984). The results revealed a significant increase (22%) in plasma TBARS (Paired TTest  $p < 0.05$ ) following exercise ( $0.74 \mu\text{M} \pm 0.2$  pre-,  $0.92 \mu\text{M} \pm 0.2$  post exercise). In order to audit for increases occurring as a direct result of concentrated blood volumes post-exercise, PCV (packed cell volumes) and plasma albumin were measured. Results did not reveal a significant difference pre- and post-exercise ( $p > 0.05$ ) and therefore the observations from this study suggest that augmented lipid peroxidation *in vivo* occurs as a direct result of exercise-induced oxidative stress. Literature proposes that the specific site of oxidative damage is the cellular membrane, where peroxyl radicals ( $\text{RO}_2$ ) proliferate in conditions of high oxidative stress. This observation infers a potential role for dietary lipid-phase antioxidant intervention in healthy adult dogs.

15

20

25

Other examples of the antioxidative status of animals and the effects of the inventive

antioxidant cocktail on animals are described below.

Example 13

Dietary Carotenoid Absorption in the Domestic Cat.

5

It is found that antioxidants, such as beta-carotene and lycopene, incorporated into commercial cat food will result in a significant increase in the absorption of carotenoids in cats, despite their metabolic carnivorous adaptation. In this study three canned cat diets were manufactured using the same batch of raw ingredients with an identical base recipe. The control diet, Diet A, had a metabolisable energy (ME) content of 3.39 MJ/kg with a beta-carotene and lycopene content of >0.1 mg/1.67 MJ ME. Diet B was supplemented with red palm oil (3.70 MJ ME/kg) with a beta-carotene content of 0.36 mg/1.67 MJ ME, and a lycopene content of >0.1 MG/1.67 MJ ME and Diet C was supplemented with tomato pumice (3.54 MJ ME/kg) with a beta-carotene content of >0.1 MG/1.67 MJ ME and a lycopene content of 0.9 MG/1.67 MJ ME.

Two groups of five healthy cats each were selected for the study. The cats of Group 1 had a mean age of 8.72 years (SD 2.1 years) and included 3 males and 2 females. The Group 2 cats had a mean age of 7.4 years (SD 1.7 years) and included 2 males and 3 females. All of the study cats were previously maintained on a variety of commercial, nutritionally complete, prepared cat food and then were maintained on Diet A for a period of seven days to allow acclimation to the diet. On day eight of the study, a baseline plasma carotenoid level was determined. Subsequently, Group 1 cats were fed Diet B and Group 2 cats were fed Diet C, for a period of five days. On day 13 of the study, a plasma sampling was repeated in the same manner as for the baseline samples. The analyses were carried out by High Performance Liquid Chromatography.

30 The beta-carotene concentration of the Group 1 cats on Diet B, increased significantly

(mean 17.62 ng/mL, SD 2.50 ng/mL) above the baseline values (mean 6.35 ng/mL, SD 3.23 ng/mL). In this group, the plasma lycopene concentrations remained below the limit of detection. In the Group 2 cats, on Diet C, there was no significant change in the plasma beta-carotene concentrations of the baseline levels (mean 5.30 ng/mL, SD 5.78 ng/mL) and the post-feeding levels (mean 6.61 ng/mL, SD 2.83ng/mL). However, Group 2 cats showed a significant increase in plasma lycopene concentrations from a baseline level of 0 ng/mL to a post-feeding level of mean 14.6 ng/mL, SD 7.25 ng/mL.

Thus, this study demonstrates that natural sources of antioxidants, such as beta-carotene and lycopene, incorporated into commercial cat food will result in a significant increase in the absorption of carotenoids in cats, despite the metabolic carnivorous adaption. This increase in circulating antioxidants will provide a beneficial effect to the antioxidative status of cats. This increased absorption of carotenoids in cats has not heretofore been seen at such low dietary concentrations.

#### Example 14

Maternal milk may be insufficient to promote a maximal antioxidant status in the developing kitten.

With respect to immune function, the effect of antioxidants is equally applicable to animals who have a compromised immune function due to age, e.g. growing animals, as well as those experiencing immunological challenges. The results of the following study show that maternal milk may be insufficient to promote a maximal antioxidant status in the developing kitten, which in turn may contribute to the increased susceptibility of kittens to oxidative stress. Thus, it can be found that the administration of an antioxidant cocktail as a dietary supplement for kittens will likewise show an improvement in antibody response time as is found in puppies receiving the antioxidant cocktail supplement.

The ability of mammals to resist oxidative insult depends on both their endogenous antioxidant defense systems and the contribution to overall antioxidant status provided by diet. One way to measure an animal's antioxidant status is to evaluate its total plasma antioxidant capacity (TPAO). A colormetric assay kit manufactured by Randox Laboratories Ltd. has been validated for use in cats to assay the normal range of TPAO. Antioxidants present in blood samples will cause suppression of the color production in the assay proportional to their blood concentration.

This study was conducted to determine the normal range of TPAO in healthy kittens and to determine whether there is any relationship between age and TPAO. Plasma samples were obtained from 16 health kittens (8 males, 8 females) at 14, 35 and 60 days of age. The samples were assayed using the method as described above and the results were compared using ANOVA. The results are illustrated in table 7 below:

Table 7.

Age of Kittens	TPAO
14 days	$0.694 \pm 0.069$
35 days	$0.853 \pm 0.083$
60 days	$1.030 \pm 0.113$

From the results, it can be seen that the TPAO status of suckling kittens is at the bottom end of the normal adult range, only achieving adult levels between 35 and 60 days. At 14 days after birth, kittens are completely dependent upon maternal milk to provide their nutritional requirements. At 35 days of age the kittens are far less dependent on maternal milk and obtain the majority of their nutritional intake from solid foods, while at 60 days they are fully weaned. These results suggest that maternal milk is insufficient to promote maximal antioxidant status in the developing kitten, which in turn contributes to the increased susceptibility of kittens to oxidative stress.

Example 15

The antioxidant fortified diet increases the antioxidant capacity of cats.

5 A group of 46 healthy domestic short haired cats were randomly stratified into 2 groups of 23 cats dependent upon age and sex. Group A were maintained on a control base diet (a complete wet diet according to the reference section) and Group B on a wet diet supplemented with an antioxidant cocktail for a period of 30 weeks.

The cocktail was:

10

	Vitamin E	50IU/400kcal diet
	Vitamin C	20mg/400kcal diet
	Beta-carotene	0.5-1mg/400kcal diet
	Lutein	0.5mg/400kcal diet
15	Taurine	200mg/400kcal diet
	Lycopene	1mg/400mg kcal diet

20 Fasting samples were obtained from all cats and assessed for antioxidant capacity using the ferric reducing antioxidant power (FRAP) and the ferric reducing antioxidant power and ascorbic acid concentration (FRASC) assays.

The antioxidant capacity was significantly increased ( $p < 0.05$ ) in Group B compared to Group A with respect to both FRAP and FRASC.

	GROUP	MEAN FRAP $\pm$ SD	MEAN FRASC $\pm$ SD
	A	260.45 $\pm$ 55.59	28.05 $\pm$ 7.93
25	B	297.63 $\pm$ 57.18	36.33 $\pm$ 10.69

Hence, the antioxidant capacity was increased in cats fed the antioxidant fortified diet, which confers an increased ability to mitigate the deleterious effects associated with oxidative insult.



Example 16

Influence of the antioxidant supplemented diet on the immunological status of cats

5

*EXPERIMENTAL DESIGN:*

10

15

48 normal healthy cats were fed a control diet (complete diet as per the reference section) for six weeks after which baseline measurements were taken. Cats were then allocated to either control or treatment age -matched groups and fed the supplemented diet described in Example 15. At week eight the animals were sampled in order to determine serum immunoglobulin concentrations. At week twelve immune parameters were measured and the cats were immunised (using a standard combined vaccine against Feline Panleucopenia, Feline Calicivirus and Feline Herpesvirus). At week

*METHODS USED:-*

20

25

*Assessment of peripheral blood mononuclear cellular (PBMC) proliferative response by mitogen induced lymphocyte transformation assay (MILT)*

Peripheral blood mononuclear cells were isolated from heparinised blood by density gradient centrifugation on Histopaque 1077(Sigma). The cells were washed twice with phosphate buffered saline (PBS) and once with RPMI-1640 (Dutch modification) supplemented with 10 per cent heat inactivated fetal calf serum, 1 per cent penicillin/streptomycin and 2 per cent sodium pyruvate. Cell viability was assessed by the trypan blue exclusion test (Sigma).

30

Cells were cultured in triplicate at  $1 \times 10^5$  per well in 96 well flat bottomed microtitre plates at  $37^{\circ}\text{C}$ , with phytohaemagglutinin (PHA) ( $5 \mu\text{g/ml}$ )(Murex), concanavalin A (Con A) ( $7.5 \mu\text{g/ml}$ ) and pokeweed mitogen (PWM)( $1 \mu\text{g/ml}$ )(Sigma) for 96 hrs.

Proliferation was measured by [<sup>3</sup>H]-thymidine incorporation in counts per minute (CPM) (0.5 µCi/well) during the final 18 hrs of culture.

Analysis of lymphocyte subsets by flow cytometry

- 5 CD4 and CD8 positive cells are the most well characterised lymphocyte subsets in feline immunology and an adequate repertoire of these cells is indicative of a healthy immune system. The assay was performed using both purified lymphocytes and whole blood and a selection of various monoclonal antibodies (Mabs).

10

RESULTS

*Assessment of PBMC proliferative response by mitogen induced lymphocyte transformation assay (MILT)*

- 15 Table 8 shows the response of PBMC to the mitogens PHA, Con A and PWM prior to and post immune challenge Mitogen induced lymphocyte transformation assay (MILT) data showed no significant changes in proliferative response for either control or treatment groups. When an analysis of stimulation indices was undertaken there was a significant decrease in the treatment group in both the PHA stimulation index (S
- 20 I) ( $p < 0.05$ ) and the Con A index ( $p < 0.001$ ) from pre to post-immunisation. There was no significant difference in the SI of the control group. The Pokeweed SI increased significantly from baseline to pre-immunisation in both groups ( $p < 0.05$ ) and decreased significantly in the treatment group post immunisation ( $p < 0.01$ ).

- 25 Table 8.

The response of PBMC to the mitogens PHA, Con A and PWM prior to and post immune challenge.

[ <sup>3</sup> H]thymidine incorporation (counts per min) CPM x 10 <sup>-3</sup> MEAN ± SEM						
Stimulation index (S.I.) MEAN ± SEM						
	Baseline		Pre-immunisation		Post-immunisation	
	standard <sup>a</sup> (n = 22)	lara plus <sup>b</sup> (n = 23)	standard (n = 22)	lara plus (n = 23)	standard (n = 22)	lara plus (n = 23)
Unstimulated	20 ± 4	21.6 ± 4	27.2 ± 3.6	18.2 ± 3	30.9 ± 3.9	25 ± 2.6
PHA	38.8 ± 4	41.5 ± 6	33.7 ± 3.9	28.5 ± 3.2	38.8 ± 4	33.3 ± 3
S.I.	2.01 ± 0.2	2.69 ± 0.5	1.38 ± 0.1	2.2 ± 0.25	1.8 ± 0.58	1.49 ± 0.14 *
Con A	29 ± 3	32.4 ± 4.5	31.4 ± 3.5	38 ± 5.9	37.9 ± 4	33 ± 3.6
S.I.	1.55 ± 0.1	1.85 ± 0.2	1.38 ± 0.1	2.3 ± 0.1	1.81 ± 0.5	1.46 ± 0.15 ***
PWM	21.5 ± 2.5	22 ± 4	37 ± 4.2	29.7 ± 3	37.8 ± 4	29.7 ± 3.3
S.I.	1.1 ± 0.1	1.25 ± 0.15	1.5 ± 0.2 *	2.52 ± 0.4 *	2.03 ± 0.7	1.26 ± 0.1 **

<sup>a</sup> control group, standard diet      \* P < 0.05 ; \*\* P < 0.01 ;

<sup>b</sup> treatment group, test diet      \*\*\* P < 0.001

## 5 Analysis of lymphocyte subsets by flow cytometry

Table 9 shows T-cell relative subset counts and CD4+: CD8+ ratio pre and post immunisation. When CD4 and CD8 T-cell subsets were analysed there was a significant increase in percentage of CD4 positive cells (p<0.05) in both groups and a significant increase in CD8 positive cells in both the control group (p< 0.05) and test group (p<0.001) post immunisation.

When the CD4 +: CD8 + ratio of lymphocytes was examined it was found to be decreased significantly in the control group (p<0.001) while remaining constant in the treatment group post immune challenge. When examining age relationships there was a trend towards a decreasing CD4+: CD8+ ratio with increasing age in the control group prior to immunisation (r = -0.483, p<0.05).

Table 9

T-cell relative subset counts and CD4+: CD8+ ratio pre and post immunisation,  
MEAN  $\pm$  SEM

	Pre immunisation		Post immunisation	
	standard <sup>a</sup> (n = 21)	lara plus <sup>b</sup> (n = 23)	standard (n = 21)	lara plus (n = 23)
CD4 positive percentage	22.6 $\pm$ 1.1	20.9 $\pm$ 0.7	25.1 $\pm$ 1.6 *	24.5 $\pm$ 1.3 *
CD8 positive percentage	17.2 $\pm$ 0.1	15.4 $\pm$ 1.3	22.3 $\pm$ 1.2 *	19.6 $\pm$ 1.6 **
CD4:CD8 ratio	1.42 $\pm$ 0.1	1.57 $\pm$ 0.1	1.17 $\pm$ 0.1 **	1.43 $\pm$ 0.1

<sup>a</sup> control group, standard diet

\* P < 0.05 ; \*\* P < 0.001

<sup>b</sup> treatment group, test diet

5

10

The observed difference in SI of PWM stimulated cells from cats fed the supplemented diet (Table 8) suggests that there is a beneficial upregulation of CD2, an activation marker of T-cells.

15

The results on Table 9 show clearly the beneficial effects of the supplemented diet on the CD4:CD8 ratios of cats post-vaccination. The CD4:CD8 ratio in the supplemented cats was maintained post vaccination compared to the control group. This maintenance is mainly due to an increase in CD4.

20

These facts show beneficial effects of the supplement upon the immune response of cats.

Example 17

## Effects of an Antioxidant Cocktail on Specific Antibody Responses of Young Dogs

- Litters of Labrador and Greyhound Puppies were separated into two age and sex –  
5 matched groups.
- One group of each breed had their standard diet (complete, as per the reference  
section) supplemented with a cocktail (details given below), the other two groups  
(one of each breed), remained on an unsupplemented diet.

## 10 Antioxidant Cocktail-

	alpha-tocopherol	50mg / 400kcal
	ascorbate	20mg /400kcal dry (40mg if wet)
	beta-carotene	0.5mg /400kcal
15	lutein	0.5mg /400kcal
	taurine	200mg /400kcal dry (500mg if wet)

- Supplement was administered for up to a maximum of four weeks prior to  
20 vaccination.
- All of the puppies were vaccinated according to routine vaccination procedures  
(vaccines included Parvo-virus and Distemper).
- Antibody levels to vaccine antigens were measured for all puppies.
- Some of these results are shown on Figures 4, 5 and 6.
- 25 • These results clearly indicate that puppies receiving a supplement of the  
antioxidant cocktail will mount a faster response to specific antigens such as are  
introduced *via* a vaccine or which may be introduced through exposure to an  
infectious agent.
- These results show that the antioxidant cocktail has a highly beneficial effect on  
30 the immune response of young animals.

Example 18

## Beneficial Effects of Antioxidant Cocktail on the Maintenance of a Vaccine Response in Adult and Senior Dogs

- Two groups of dogs were age, sex and breed matched.
- Both groups were further matched in accordance to when they had previously been vaccinated (prior to the start of the study).
- One group was fed a diet supplemented with an antioxidant cocktail (details given below), the other group remained an unsupplemented control.

Table 10

Antioxidant Content of Diet	Supplemented Test Diet	Control Diet
<i>Vitamin E</i>	52.41 IU/400 kcal	4.81 IU/400 kcal
<i>Vitamin C</i>	65.9 mg/400 kcal	2.48 mg/400 kcal
<i>Taurine</i>	0.16%	0.054%
<i>Carotenoids</i>		
- <i>Cis Beta-carotene</i>	11.07 ug/400 kcal	<10.96 ug/400 kcal
- <i>Trans Beta-carotene</i>	33.21 ug/400 kcal	21.91 ug/400 kcal
- <i>Trans Alpha-carotene</i>	<11.07 ug/400 kcal	10.96 ug/400 kcal
- <i>Cis Alpha-carotene</i>	<11.07 ug/400 kcal	<10.96 ug/400 kcal
- <i>Lutein</i>	0.996 mg/400 kcal	0.877 mg/400 kcal
- <i>Lycopene</i>	<11.07 mg/400 kcal	<10.96 ug/400 kcal
- <i>Xeaxanthian</i>	1.22 mg/400 kcal	1.32 mg/400 kcal

- After a period of six months on the supplemented diet the dogs had their circulating anti-adenovirus antibody titre measured. Results are shown on the graph in Figure 7.
- These results show that animals fed a diet containing an antioxidant cocktail are better able to maintain vaccine induced antibodies over time than are unsupplemented dogs.

Example 19

The antioxidant status and oxidative damage in dogs fed a canine dry diet containing an antioxidant cocktail after 8 weeks.

5     Summary:

- This report contains results (antioxidant status and oxidative damage) from dogs fed a canine dry diet containing an antioxidant cocktail for 8 weeks. Some of the results were influenced by diet and age.
- 10     • Plasma FRAP and vitamin E levels in the Antioxidant-fed group were significantly higher than in the Control-fed group.
- Plasma vitamin E levels in both the Young Adult and Senior dogs fed the  
15     Antioxidant diet were significantly higher than in their respective Control groups.

## MATERIALS & METHODS

Animals

20

*1) Type of animals*

25

40 young adult (0.8 to 3.3 years old) and senior (6.5 to 12.5 years), pure breeds (Labradors, Beagles, West Highland white terrier, Newfoundland, & Golden Retriever), and mixed sex dogs (intact, neutered/spayed) were included in the study.

*2) Housing*

Dogs were grouped in pairs and had access to the outside environment from their pens. All dogs had access to indoors during day and night times. Dogs

from the same treatment group were housed together to prevent cross contamination due to coprophagia (fecal consumption). Temperature was controlled at 22°C with natural light cycle. Dogs were allowed to follow their daily regular exercise routine.

5

### 3) *Feeding Schedule*

All dogs were on a complete and balanced canine dry diet for one week prior to the start of the study. After the one week of adaptation, two-thirds of the dogs remained on the base diet as the control group, while the remaining third was switched over to the test diet. The amount of food fed to each dog was based on the ME equation ( $110 \times BW^{0.75}$  Kcal). The amount of food fed to each dog was adjusted accordingly to maintain bodyweight. All dogs had access to fresh water at all times.

10

### 15 Test Substance

The test diet contained the following ingredients that were not added to the control diet.

Ingredients	% Added to diet
Tomato Pomace	5
Vitamin C 35%	0.18
Taurine	0.14
Vitamin E 50%	0.12
Marigold Meal	0.04

### 20 Trial Design

The study was a longitudinal test design. All dogs were randomly assigned based on breed, sex, age, body weight and health status.

Groups	n's per group	Age (yrs)	Diets	Test Period
--------	---------------	-----------	-------	-------------



Control (A,B,E,F)	26	5.5 ± 4.3	Control Diet (w/o antioxidant cocktail)	8 weeks
Test (C, G)	14	5.9 ± 4.4	Antioxidant Cocktail Diet	8 weeks

Same dogs as the above table, however, they were broken down by age.

Groups	n's per group	Avg age w/in each group (years ± SD)	Diets	Test Period
Young Adult Control (A,B)	12	1.2 ± 0.8	Control Diet	8 weeks
Young Adult Test (C)	6	1.0 ± 0.1	Antioxidant Cocktail Diet	8 weeks
Senior Control (E,F)	14	9.3 ± 2.0	Control Diet	8 weeks
Senior Test (G)	8	9.5 ± 1.5	Antioxidant Cocktail Diet	8 weeks

- 5 *Blood and saliva biomarkers:* Bloods were collected from each dog to measure the following parameters at 8 weeks after the treatment.

Antioxidants/Damage	Description
Plasma vitamin E	Fat soluble antioxidant
Plasma FRAP/FRASC	A measure of "Antioxidant Power" in plasma & ascorbic acid level

#### Statistics

- 10 Analyses were determined for all dogs for all parameters by unequal n's Tukey's post hoc test for statistical significance between treatment at  $p < 0.05$ . Data are expressed as group means ± SD.

- 15 Figure 8: The measurement of ferric reducing ability of plasma (FRAP) that measures the "antioxidant capacity" in dogs fed a canine dry diet containing an antioxidant cocktail for a period of 8 weeks. (Control, n=26; Test, n=14). \*Represents significant differences from the Control group,  $p < 0.05$ .

- The measurement of plasma "antioxidant capacity" in the Test group was significantly higher than in the Control group after 8 weeks of treatment.

Figure 9: The measurement of plasma vitamin E levels in dogs fed a canine dry diet containing an antioxidant cocktail for a period of 8 weeks. (Control, n=26; Test, n=14). \*Represents significant differences from the Control group,  $p < 0.05$ .

- Plasma vitamin E level in the Test group was significantly higher than in the Control group after 8 weeks of treatment.

#### Reference Diet Section

Nutritionally complete diet

A complete diet for foodstuff, especially a nutritionally complete petfood (or diet) is a diet which meets all the nutritional requirements of the individual animal's lifestyle and lifestage.

The diet or foodstuff can be made according to any method known in the art, such as in Waltham Book of Dog and Cat Nutrition, Ed. ATB Edney, Chapter by A. Rainsbird, entitled "A Balanced Diet" in pages 57 to 74, Pergoren Press Oxford.

The following shows a composition of a complete balanced diet according to the Examples.

<u>Ingredient</u>	<u>Inclusion</u>
Rice	24.9%
Whole corn	18.8%
Whole grain wheat	12.2%

	Chicken by-product meat	18.7%
	Corn gluten meal	9.5%
	Brewers yeast	1.7%
	Dried egg	0.8%
5	Non-iodinised salt	0.7%
	Vitamin premix	3.4%
	Sunflower oil	0.5%
	Beef tallow	4.9%
	Poultry viscera	4.4%
10	Analytical profile – moisture 8.2%, protein 26.4%, fat 10.4%, ash 7.1%, fibre 2.2% (the remainder being made up of nitrogen-free extract (mainly carbohydrate)).	

Claims:

1. A method for increasing the plasma vitamin E level in a cat or dog, the method comprising the step of administering to said cat or dog, an amount of Vitamin E sufficient to increase the plasma vitamin E level.
2. A method, as claimed in claim 1, further comprising administering to said cat or dog, an amount of vitamin C.
3. A method, as claimed in claim 1 or claim 2, further comprising administering to said cat or dog, an amount of taurine.
4. A method, as claimed in claim 1 or claim 2, further comprising administering to said cat or said dog, an amount of vitamin C and an amount of taurine.
5. A method as claimed in any one of claims 1 to 5, further comprising administering to said cat or dog, an amount of a carotenoid.
6. A method as claimed in any one of claims 2 to 6, wherein the components are administered simultaneously, separately, or sequentially.
7. A dog or cat foodstuff which delivers to said animal, a concentration of ingredients sufficient to increase the antioxidant status of the animal.
8. A dog or cat foodstuff which provides a concentration of vitamin E at a level of 25IU/400kcal diet or above.
9. A dog or cat foodstuff as claimed in claim 10, which provides a concentration of vitamin C at a level of 10mg/400kcal or above.

10. A dog or cat foodstuff as claimed in claim 10, which provides a concentration of taurine at a level of 80mg/400kcal or above.
- 5 11. A dog or cat foodstuff as claimed in claim 10, which provides a concentration of vitamin C at a level of 10mg/400kcal, or above and which provides a concentration of taurine at a level of 80mg/400kcal or above.
- 10 12. A dog or cat foodstuff as claimed on any one of claims 7 to 11, which provides a concentration of a carotenoid.
13. A dog or cat foodstuff as claimed in any one of claims 7 to 12, for use in the prevention or treatment of low antioxidant status in a dog or cat.
- 15 14. A dog or cat foodstuff as claimed in any one of claims 7 to 12, for use in the prevention or treatment of any disorder which has a component of stress.
- 20 15. A dog or cat foodstuff as claimed in claim 14, wherein the disorder is any one or more of; cancer, ageing, heart disease, atherosclerosis, arthritis, cataracts, inflammatory bowel disease, renal disease, renal failure, neurodegenerative disease or compromised immunity.
16. A dog or cat foodstuff, as claimed in any one of claims 7 to 14 for use in treating or assisting a cat or a dog in response to an immune challenge.
- 25 17. A foodstuff as claimed in claim 16, wherein the immune challenge is vaccination.
- 30 18. A method for preventing or treating a dog or cat suffering from a disorder which has a component of oxidative stress comprising feeding to said dog or cat a foodstuff as claimed in any one of claims 7 to 12.

19. A method of maintaining optimising or boosting an immune response to an immunological challenge in an animal comprising feeding said animal a foodstuff as claimed in any one of claims 7 to 12.
- 5
20. Use of vitamin E, in the manufacture of a medicament for the prevention or treatment of low antioxidant status in a dog or cat.
21. Use of vitamin E, in the manufacture of a clinical diet for the prevention or treatment of any disorder which has a component of oxidative stress.
- 10
22. Use of vitamin E, as claimed in claim 21, for maintaining, optimising or boosting an immune response, in a cat or a dog, in response to an immunological challenge.
- 15
23. Use of vitamin E, incorporated into a foodstuff as an *in vivo* antioxidant, in a dog or cat.
24. A method for making a foodstuff as claimed in any one of claims 7 to 14 or 21, the method comprising mixing together at least two ingredients of the foodstuff.
- 20
25. A dog or cat foodstuff comprising vitamin C at a concentration of 15mg/400kcal or above.
- 25
26. Use of vitamin C in the manufacture of a dog or cat foodstuff for the prevention or treatment of a disorder which has a component of oxidative stress.
27. Use of vitamin C as claimed in claim 26, wherein the disorder is any one or more of, cancer, ageing, heart disease, atherosclerosis, arthritis, cataracts,

inflammatory bowel disease, renal disease, renal failure, neurodegenerative disease or compromised immunity.

5 28. Use of vitamin C as claimed in claim 26 for treating or assisting in response to an immunological challenge

29. A method for prevention or treatment in a cat or a dog of a disorder which has a component of oxidative stress comprising feeding said cat or dog a foodstuff as claimed in claim 25.

10

30. A dog or cat foodstuff as claimed in claim 7 which comprises:

15                   alpha-tocopherol  
                  ascorbate  
                  beta-carotene  
                  lutein and  
                  taurine.

20 31. A dog or cat foodstuff as claimed in claim 30 which also comprises:  
                  lycopene

32. A dog or cat foodstuff as claimed in claim 30, wherein the components present as follows:

25                   alpha-tacopherol:       from 25IU/400kcal  
                  ascorbate:           from 5mg/kcal  
                  beta-carotene:       from 0.01mg/400kcal  
                  lutein:               from 0.05mg/400kcal  
                  taurine:           from 80mg/400kcal

30

33. A dog or a cat foodstuff as claimed in claim 32 further comprising lycopene at a concentration of from 0.01mg/400kcal.



1 / 4

FIG. 1





FIG. 2



2 / 4

FIG. 3



VITAMIN E PLASMA STATUS IN CATS REFLECTING  
DIETARY VITAMIN E SUPPLEMENTATION

FIG. 4

ANTI-PARVOVIRUS ANTIBODY TITRES



3 / 4

FIG. 5





FIG. 6



4 / 4

FIG. 7



MAINTAINANCE OF ANTI-ADENOVIRUS ANTIBODY TITRES IN  
DOGS SUPPLEMENTED WITH AN ANTIOXIDANT COCKTAIL

FIG. 8




FIG. 9

# INTERNATIONAL SEARCH REPORT

Intern Application No  
PCT/GB 00/00270

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/355 A61K31/375 A23K1/16 A23K1/18 A61P9/00  
A61P13/12 A61P19/02 A61P25/00 A61P27/12 A61P29/00  
A61P37/00 A61P39/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A23K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 848 955 A (SHOWA DENKO KK) 24 June 1998 (1998-06-24)  page 4, line 54 - line 56 page 5, line 35 -page 7, line 50 example 3 claims 1-9	1,2,5-7, 12-14, 18,20, 21, 23-26,29
Y	---	3,4,30
Y	US 5 141 755 A (WEISMAN ERIC H) 25 August 1992 (1992-08-25) claims 1,4-6,8  ---	3,4,30
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 May 2000

Date of mailing of the international search report

24/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Dekeirel, M

# INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/GB 00/00270

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 199723 Derwent Publications Ltd., London, GB; Class B05, AN 1997-259340 XP002137042 &amp; ZA 9 605 149 A (DAVIS H J), 26 March 1997 (1997-03-26) abstract</p>	<p>1,2,5-7, 12-14, 16, 18-24, 26,28</p>
X	<p>K. PRASAD ET AL.: "Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model" JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 28, no. 2, 1996, pages 375-385, XP000909089 ACADEMIC PRESS, LONDON, GB ISSN: 0022-2828 page 375, abstract</p>	<p>1,7, 13-15, 18,20, 21,23</p>
P,X	<p>WO 00 01399 A (COASTSIDE BIO RESOURCES ;COLLIN PETER DONALD (US)) 13 January 2000 (2000-01-13)  page 1, line 12 - line 15 page 3, line 18 - line 27 examples 1-3</p>	<p>1,7, 13-15, 18,20, 21,23,24</p>
Y	<p>DATABASE WPI Section Ch, Week 199521 Derwent Publications Ltd., London, GB; Class B07, AN 1995-157784 XP002137041 -&amp; JP 07 079712 A (SANEIGEN FFI KK), 28 March 1995 (1995-03-28) abstract</p>	<p>1,5-7, 12,13, 23,24</p>
Y	<p>GB 2 185 673 A (MITSUBISHI GAS CHEMICAL CO) 29 July 1987 (1987-07-29)  page 2, line 40 - line 49</p>	<p>1,5-7, 12,13, 23,24</p>
X	<p>US 3 384 545 A (AIELLO RONALD EUGENE ET AL) 21 May 1968 (1968-05-21) column 1, line 67 -column 2, line 22 column 4, line 8 - line 14 examples 1,2,4</p>	<p>1</p>
X	<p>EP 0 015 721 A (FOX EDWARD SOLOMON) 17 September 1980 (1980-09-17) example</p>	<p>25-27,29</p>
	-/-	

# INTERNATIONAL SEARCH REPORT

Interr. Application No  
PCT/GB 00/00270

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 834 262 A (NICHIMO KK) 8 April 1998 (1998-04-08) page 5, line 56 -page 6, line 27 page 12, line 51 -page 13, line 17 claims 1-3	7,13-15, 18,24
X	WO 97 35491 A (ASTACAROTENE AB ;SVENSKA FODER AB (SE); LIGNELL AAKE (SE); INBORR) 2 October 1997 (1997-10-02) page 1, line 15 - line 21 page 2, line 11 - line 26 claims 1-11	7,12-16, 18,19,24

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/GB 00/00270

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0848955 A	24-06-1998	JP 10175866 A US 5937790 A	30-06-1998 17-08-1999
US 5141755 A	25-08-1992	NONE	
ZA 9605149 A		NONE	
WO 0001399 A	13-01-2000	NONE	
JP 7079712 A	28-03-1995	NONE	
GB 2185673 A	29-07-1987	JP 1684153 C JP 3038823 B JP 62158457 A JP 62195254 A	31-07-1992 11-06-1991 14-07-1987 28-08-1987
US 3384545 A	21-05-1968	NONE	
EP 0015721 A	17-09-1980	GB 2042337 A	24-09-1980
EP 0834262 A	08-04-1998	US 6045819 A WO 9737549 A	04-04-2000 16-10-1997
WO 9735491 A	02-10-1997	SE 506191 C AU 716605 B AU 2313397 A CA 2249456 A CZ 9803029 A EP 0912106 A NZ 331861 A PL 328996 A SE 9601197 A	17-11-1997 02-03-2000 17-10-1997 02-10-1997 17-02-1999 06-05-1999 28-10-1999 01-03-1999 28-09-1997